Menhibrix Approved to Prevent Bacterial Infections in Infants

Approval covers infants and toddlers ages 6 weeks through 18 months

FRIDAY, June 15 (HealthDay News) -- The combination vaccine Menhibrix has been approved by the U.S. Food and Drug Administration to prevent two deadly bacterial infections among infants and toddlers -- Neisseria meningitides serogroups C and Y and Haemophilus influenzae type b.

The approval covers youngsters aged 6 weeks through 18 months, the agency said in a news release.

The vaccine's safety and effectiveness were clinically evaluated among 7,500 infants and toddlers in the United States, Mexico, and Australia, the agency said. Common adverse reactions included pain, injection-site redness and swelling, irritability, and fever.

The GlaxoSmithKline vaccine is given as a four-dose series, starting as early as 6 weeks of age, the FDA said.

More information

To learn more about this approval, visit the FDA.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events